Skip to main content

Table 5 Number of patients with periprocedural complications within 48 h

From: Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants

 

Group A

Bridging

(n = 111)

Group B

VKA

(n = 318)

Group C

DOAC

(n = 351)

OR (95% CI)

p-value

A-B

OR (95% CI)

p-value

A-C

OR (95% CI)

p-value

B-C

Major complications

9 (8.1%)

8 (2.5%)

10 (2.8%)

3.42 (1.29–9.10)

0.019

3.01 (1.19–7.61)

0.025

1.14 (0.44–2.92)

0.816

 Major without cerebrovascular accidents

8 (7.2%)

5 (1.6%)

6 (1.7%)

4.86 (1.56–15.99)

0.006

4.466 (1.52–13.67)

0.007

1.09 (0.33–3.60)

1.0

  Major pericardial effusion

3 (2.7%)

2 (0.6%)

3 (0.9%)

4.39 (0.72–26.62)

0.112

3.22 (0.64–16.20)

0.153

1.36 (0.23–8.20)

1.0

  Major vascular

3 (2.7%)

3 (0.9%)

1 (0.3%)

2.92 (0.58–14.67)

0.182

9.72 (1.00–94.43)

0.045

0.30 (0.03–2.90)

0.351

 Cerebrovascular complications

1 (0.9%)

3 (0.9%)

4 (1.1%)

0.96 (0.10–9.27)

1.0

0.79 (0.09–7.13)

1.0

1.21 (0.27–5.45)

1.0

Minor complications

9 (8.1%)

24 (7.5%)

26 (7.4%)

1.08 (0.49–2.40)

0.838

1.10 (0.50–2.43)

0.837

0.98 (0.55–1.75)

1.0

 Minor pericardial effusion

0 (0.0%)

4 (1.3%)

7 (2.0%)

0.577

0.204

1.60 (0.46–5.51)

0.551

 Minor vascular complication

7 (6.3%)

16 (5.0%)

17 (4.8%)

1.27 (0.51–3.17)

0.627

1.32 (0.53–3.28)

0.623

0.96 (0.48–1.94)

1.0

 GI haemorrhage

0 (0.0%)

1 (0.3%)

0 (0.0%)

0.213

1.0

1.0

Groin haemorrhage

4 (3.6%)

4 (1.3%)

3 (0.9%)

2.94 (0.72–11.94)

0.066

4.34 (0.96–19.68)

0.060

0.68 (0.15–3.05)

0.714

 Major

2 (1.8%)

0 (0.0%)

1 (0.3%)

0.651

3.20 (0.45–23.00)

0.145

− 

0.50

 Minor

2 (1.8%)

4 (1.3%)

2 (0.6%)

1.44 (0.26–7.97)

0.019

6.42 (0.58–71.51)

0.245

0.22 (0.03–2.02)

0.196

  1. Legend: Bridging interrupted vitamin-K-antagonist, CI confidence interval, DOAC uninterrupted non-vitamin-K anticoagulants, OR odds ratio, VKA uninterrupted vitamin-K-antagonist